798 related articles for article (PubMed ID: 11485970)
21. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation.
Kandalam V; Basu R; Abraham T; Wang X; Soloway PD; Jaworski DM; Oudit GY; Kassiri Z
Circ Res; 2010 Mar; 106(4):796-808. PubMed ID: 20056917
[TBL] [Abstract][Full Text] [Related]
22. MMP induction and inhibition in myocardial infarction.
Lindsey ML
Heart Fail Rev; 2004 Jan; 9(1):7-19. PubMed ID: 14739764
[TBL] [Abstract][Full Text] [Related]
23. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
[TBL] [Abstract][Full Text] [Related]
24. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling.
Lindsey ML; Iyer RP; Jung M; DeLeon-Pennell KY; Ma Y
J Mol Cell Cardiol; 2016 Feb; 91():134-40. PubMed ID: 26721597
[TBL] [Abstract][Full Text] [Related]
25. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
26. Matrix metalloproteinases and myocardial infarction.
Phatharajaree W; Phrommintikul A; Chattipakorn N
Can J Cardiol; 2007 Jul; 23(9):727-33. PubMed ID: 17622396
[TBL] [Abstract][Full Text] [Related]
27. Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction.
Hayashidani S; Tsutsui H; Shiomi T; Suematsu N; Kinugawa S; Ide T; Wen J; Takeshita A
Circulation; 2002 Feb; 105(7):868-73. PubMed ID: 11854129
[TBL] [Abstract][Full Text] [Related]
28. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
29. Extracellular matrix remodeling attenuated after experimental postinfarct left ventricular aneurysm repair.
Hsu CP; Huang CY; Wang JS; Sun PC; Shih CC
Ann Thorac Surg; 2008 Oct; 86(4):1243-9. PubMed ID: 18805169
[TBL] [Abstract][Full Text] [Related]
30. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
[TBL] [Abstract][Full Text] [Related]
31. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
George SJ
Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
[TBL] [Abstract][Full Text] [Related]
32. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
[TBL] [Abstract][Full Text] [Related]
33. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure.
Peterson JT; Hallak H; Johnson L; Li H; O'Brien PM; Sliskovic DR; Bocan TM; Coker ML; Etoh T; Spinale FG
Circulation; 2001 May; 103(18):2303-9. PubMed ID: 11342481
[TBL] [Abstract][Full Text] [Related]
34. Selective targeting of matrix metalloproteinase inhibition in post-infarction myocardial remodeling.
Apple KA; Yarbrough WM; Mukherjee R; Deschamps AM; Escobar PG; Mingoia JT; Sample JA; Hendrick JW; Dowdy KB; McLean JE; Stroud RE; O'Neill TP; Spinale FG
J Cardiovasc Pharmacol; 2006 Feb; 47(2):228-35. PubMed ID: 16495760
[TBL] [Abstract][Full Text] [Related]
35. Temporal changes in myocardial collagen, matrix metalloproteinases, and their tissue inhibitors in the left ventricular myocardium in experimental chronic mitral regurgitation in rodents.
Corporan D; Onohara D; Hernandez-Merlo R; Sielicka A; Padala M
Am J Physiol Heart Circ Physiol; 2018 Nov; 315(5):H1269-H1278. PubMed ID: 30141979
[TBL] [Abstract][Full Text] [Related]
36. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
Janssens S; Lijnen HR
Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
[TBL] [Abstract][Full Text] [Related]
37. Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice.
Kassiri Z; Oudit GY; Sanchez O; Dawood F; Mohammed FF; Nuttall RK; Edwards DR; Liu PP; Backx PH; Khokha R
Circ Res; 2005 Aug; 97(4):380-90. PubMed ID: 16037568
[TBL] [Abstract][Full Text] [Related]
38. Temporal and spatial expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases following myocardial infarction.
Lindsey ML; Zamilpa R
Cardiovasc Ther; 2012 Feb; 30(1):31-41. PubMed ID: 20645986
[TBL] [Abstract][Full Text] [Related]
39. Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution.
Iyer RP; Patterson NL; Zouein FA; Ma Y; Dive V; de Castro Brás LE; Lindsey ML
Int J Cardiol; 2015 Apr; 185():198-208. PubMed ID: 25797678
[TBL] [Abstract][Full Text] [Related]
40. Differential activation of matrix metalloproteinases in heart failure with and without ventricular dilatation.
Nishikawa N; Yamamoto K; Sakata Y; Mano T; Yoshida J; Miwa T; Takeda H; Hori M; Masuyama T
Cardiovasc Res; 2003 Mar; 57(3):766-74. PubMed ID: 12618238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
